ODT / Odonate Therapeutics Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

ODT / Odonate Therapeutics Inc / Ikarian Capital, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 676079106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t

JOINT FILING AGREEMENT February 14, 2022

EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-38318 Commission File Number Odonate Therapeutics, Inc. (Exact name of registrant as specified

ODT / Odonate Therapeutics Inc / BML Investment Partners, L.P. - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Odonate Therapeutics Inc (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 676079106 (CUSIP Number) Calendar Year 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

ODT / Odonate Therapeutics Inc / BML Investment Partners, L.P. - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Odonate Therapeutics Inc (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 676079106 (CUSIP Number) January 19, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

As filed with the Securities and Exchange Commission on January 26, 2022

As filed with the Securities and Exchange Commission on January 26, 2022 Registration No.

As filed with the Securities and Exchange Commission on January 26, 2022

As filed with the Securities and Exchange Commission on January 26, 2022 Registration No.

As filed with the Securities and Exchange Commission on January 26, 2022

As filed with the Securities and Exchange Commission on January 26, 2022 Registration No.

As filed with the Securities and Exchange Commission on January 26, 2022

As filed with the Securities and Exchange Commission on January 26, 2022 Registration No.

As filed with the Securities and Exchange Commission on January 26, 2022

As filed with the Securities and Exchange Commission on January 26, 2022 Registration No.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organi

ODT / Odonate Therapeutics Inc / EcoR1 Capital, LLC Passive Investment

0UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 676079106 (CUSIP Number) December 10, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t

ODT / Odonate Therapeutics Inc / Boxer Capital, LLC - SC 13D/A Activist Investment

SC 13D/A 1 d242164dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 676079106 (CUSIP Number) David A. Brown Alston & Bird LLP 950 F Street, N.W. Washington, DC 20004-1404 202-239-

ODT / Odonate Therapeutics Inc / Boxer Capital, LLC - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.

ODT / Odonate Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 7 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Kevin Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 210 San Diego, CA 92121 (858) 200-3830 (Name, Address

ODT / Odonate Therapeutics Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 676079106 (CUSIP Number) November 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

EXHIBIT 99 Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan NEW YORK, NY-(BUSINESS WIRE)?November 17, 2021- Odonate Therapeutics, Inc.

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or orga

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odona

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2021 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odonate Th

ODT / Odonate Therapeutics Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 676079106 (CUSIP Number) July 8, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

ODT / Odonate Therapeutics Inc / Ikarian Capital, LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 676079106 (CUSIP Number) June 11, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru

JOINT FILING AGREEMENT July 2, 2021

EXHIBIT 99.1 JOINT FILING AGREEMENT July 2, 2021 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including any am

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 odt-def14a20210624.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odonate T

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 676079106 (CUSIP Number) March 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2021 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organiz

Up to $100,000,000 Odonate Therapeutics, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-233990 PROSPECTUS SUPPLEMENT (To Prospectus dated October 18, 2019) Up to $100,000,000 Odonate Therapeutics, Inc. Common Stock We have entered into an Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC (“Jefferies”), relating to shares of our common stock offered by this prospectus supplement and the accompanying p

Description of Registered Securities

Exhibit 4.1 DESCRIPTION OF REGISTERED SECURITIES General The following is a summary of the material terms of the common stock of Odonate Therapeutics, Inc. (the ?Company?, ?we? and ?our?) based on our certificate of incorporation, first amended and restated bylaws (?bylaws?) and certain provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or orga

Odonate Therapeutics, Inc. Open Market Sale Agreement

Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM February 23, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Odonate Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s co

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38318 Odonate Therap

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 676079106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Kevin Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 210 San Diego, CA 92121 (858) 200-3830 (Name, Address

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or orga

Virtual Investor and Analyst Event December 11, 2020 Forward-looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking stat

Exhibit 99.1 Virtual Investor and Analyst Event December 11, 2020 www.odonate.com Forward-looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this presentation and involve substantial

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or orga

Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine

Exhibit 99.1 Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard Ratio=0.716; p=0.003) Medi

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or orga

-

VIA EDGAR December 4, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Alan Campbell Re: Odonate Therapeutics, Inc. Registration Statement on Form S-3 Filed November 27, 2020 File No. 333-250993 Dear Mr. Campbell: Odonate Therapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests pursuant to Rule 461 u

- S-3

As filed with the Securities and Exchange Commission on November 27, 2020 Registration No.

Letter from Squar Milner LLP, dated November 4, 2020

Exhibit 16.1 November 4, 2020 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Odonate Therapeutics, Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the Company’s Current Report on Form 8-K

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2020 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organ

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odona

ODT / Odonate Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 676079106 (CUSIP Number) August 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

ODT / Odonate Therapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 5 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Kevin Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 210 San Diego, CA 92121 (858) 200-3830 (Name, Address

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2020 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organi

ODT / Odonate Therapeutics, Inc. / Boxer Capital, LLC - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.

Odonate Therapeutics, Inc. Common Stock Underwriting Agreement

Exhibit 1.1 EXECUTION VERSION Odonate Therapeutics, Inc. Common Stock, par value $0.01 per share Underwriting Agreement August 27, 2020 Jefferies LLC As representative (the “Representative”) of the several Underwriters named in Schedule I hereto, c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Odonate Therapeutics, Inc., a Delaware corporation (the “Company”), p

5,614,036 Shares Odonate Therapeutics, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-233990 PROSPECTUS SUPPLEMENT (To Prospectus dated October 18, 2019) 5,614,036 Shares Odonate Therapeutics, Inc. Common Stock We are offering 5,614,036 shares of our common stock. Our common stock is traded on the Nasdaq Global Select Market under the symbol “ODT.” On August 25, 2020, the last reported sale price per share of our commo

Subject to Completion Preliminary Prospectus Supplement dated August 26, 2020

Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-233990 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not per

Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2020 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organi

Odonate Therapeutics Announces Positive Top‑line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved P

Exhibit 99.1 Odonate Therapeutics Announces Positive Top‑line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard Ratio=0.716; p=0.003) Median PFS Was 9.8 Months for

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odonate Th

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organiza

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odonate T

ODT / Odonate Therapeutics, Inc. 10-K - Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38318 Odonate Therap

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF REGISTERED SECURITIES General The following is a summary of the material terms of the common stock of Odonate Therapeutics, Inc. (the “Company”, “we” and “our”) based on our certificate of incorporation and first amended and restated bylaws (“bylaws”) and certain provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by

ODT / Odonate Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment

odon19a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 676079106 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 676079106 (CUSIP Number) December 31, 2019 (D

ODT / Odonate Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Odonate Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 676079106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2019 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or orga

ODT / Odonate Therapeutics, Inc. S-8 - - S-8

As filed with the Securities and Exchange Commission on November 6, 2019 Registration No.

Odonate Therapeutics, Inc. 2017 Stock Option Plan (incorporated herein by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 (File No. 333-234539), as filed with the SEC on November 6, 2019)

EXHIBIT 99.1 ODONATE THERAPEUTICS, INC. 2017 STOCK OPTION PLAN 1.Purpose. The purpose of this Odonate Therapeutics, Inc. 2017 Stock Option Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of Odonate Therapeutics, Inc. (“Odonate”) and Odonate’s stockholders by providing stock-based compensation. 2.Definitions.

ODT / Odonate Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odona

ODT / Odonate Therapeutics, Inc. CORRESP - -

VIA EDGAR October 16, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Sonia Bednarowski Re: Odonate Therapeutics, Inc. Registration Statement on Form S-3 Filed September 27, 2019 File No. 333-233990 Dear Ms. Bednarowski: Odonate Therapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests pursuant to Ru

ODT / Odonate Therapeutics, Inc. / Odonate Holdings, Llc - AMENDMENT NO. 2 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Odonate Holdings, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Name, Address and Telephone Numb

ODT / Odonate Therapeutics, Inc. S-3 - - S-3

As filed with the Securities and Exchange Commission on September 27, 2019 Registration No.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2019 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or org

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2019 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organiza

ODT / Odonate Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odonate Th

Odonate Therapeutics, Inc. Common Stock Underwriting Agreement

Exhibit 1.1 EXECUTION VERSION Odonate Therapeutics, Inc. Common Stock, par value $0.01 per share Underwriting Agreement June 25, 2019 Jefferies LLC Cowen and Company, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 1

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2019 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organiza

ODT / Odonate Therapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 4 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Kevin Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Name, Address

4,750,000 Shares Odonate Therapeutics, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-229785 PROSPECTUS SUPPLEMENT (To Prospectus dated February 28, 2019) 4,750,000 Shares Odonate Therapeutics, Inc. Common Stock We are offering 4,750,000 shares of our common stock. Our common stock is traded on the Nasdaq Global Select Market under the symbol “ODT.” On June 24, 2019, the last reported sale price per share of our common

Subject to Completion Preliminary Prospectus Supplement dated June 25, 2019

Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-229785 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not per

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organiza

First Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on June 24, 2019)

Exhibit 3.1 FIRST AMENDED AND RESTATED BYLAWS OF ODONATE THERAPEUTICS, INC. (a Delaware corporation) As Adopted and Effective as of June 20, 2019 Article I MEETINGS OF STOCKHOLDERS Section 1.1Annual Meeting. The annual meeting of stockholders, for the election of directors and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, e

ODT / Odonate Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odonate T

ODT / Odonate Therapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 3 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Kevin Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Name, Address

ODT / Odonate Therapeutics, Inc. CORRESP

VIA EDGAR February 26, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Sonia Bednarowski Re: Odonate Therapeutics, Inc. Registration Statement on Form S-3 Filed February 22, 2019 File No. 333-229785 Dear Ms. Bednarowski: Odonate Therapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests pursuant to Ru

ODT / Odonate Therapeutics, Inc. S-3

As filed with the Securities and Exchange Commission on February 22, 2019 Registration No.

ODT / Odonate Therapeutics, Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38318 Odonate Therap

ODT / Odonate Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment

odon18in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 676079106 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 676079106 (CUSIP Number) December 31, 2018 (Da

ODT / Odonate Therapeutics, Inc. / Boxer Capital, LLC - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2018 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organ

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2018 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or orga

ODT / Odonate Therapeutics, Inc. / Odonate Holdings, Llc - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Odonate Holdings, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Name, Address and Telephone Numb

ODT / Odonate Therapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Kevin C. Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Name, Addre

ODT / Odonate Therapeutics, Inc. ODT Q3 10-Q MASTER (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odona

ODT / Odonate Therapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Kevin C. Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Name, Addre

ODT / Odonate Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odonate Th

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2018 Odonate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38318 82-2493065 (State or other jurisdiction of incorporation or organiza

ODT / Odonate Therapeutics, Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

ODT / Odonate Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38318 Odonate T

ODT / Odonate Therapeutics, Inc. S-8

As filed with the Securities and Exchange Commission on April 6, 2018 Registration No.

ODT / Odonate Therapeutics, Inc. 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001

Form of Stock Option Award (incorporated herein by reference to Exhibit 10.3 to the Company’s Annual Report on Form 10-K (File No. 001-38318), as filed with the SEC on February 14, 2018)

Exhibit 10.3 ODONATE THERAPEUTICS, INC. GRANT NOTICE FOR 2017 STOCK OPTION PLAN [INCENTIVE][NONQUALIFIED] STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, Odonate Therapeutics, Inc. (“Odonate” or the “Company”), hereby grants to Participant named below the [incentive][nonqualified] stock option (the “Option”) to purchase any part or all of the number of shares of its common stock, par value $0.0

Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.4 to the Company’s Annual Report on Form 10-K (File No. 001-38318), as filed with the SEC on February 14, 2018)

Exhibit 10.4 ODONATE THERAPEUTICS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN 1.Purpose. The purpose of the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan, including any sub-plans or appendices hereto (the “Plan”), is to provide an opportunity for Employees of Odonate Therapeutics, Inc., a Delaware corporation (“Odonate”) and its Participating Subsidiaries to purchase Common Stock of Odo

Odonate Therapeutics, Inc. 2017 Stock Option Plan

Exhibit 10.2 ODONATE THERAPEUTICS, INC. 2017 STOCK OPTION PLAN 1.Purpose. The purpose of this Odonate Therapeutics, Inc. 2017 Stock Option Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of Odonate Therapeutics, Inc. (“Odonate”) and Odonate’s stockholders by providing stock-based compensation. 2.Definitions.

Limited Liability Company Operating Agreement of Odonate Holdings, LLC (incorporated herein by reference to Exhibit 10.1 to the Company’s Annual Report on Form 10-K (File No. 001-38318), as filed with the SEC on February 14, 2018)

Exhibit 10.1 AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF ODONATE HOLDINGS, LLC This Amended and Restated Limited Liability Company Agreement (this “Operating Agreement”) of Odonate Holdings, LLC (“Odonate Holdings”) is made effective as of December 6, 2017 (the “Effective Date”), with respect to the holders of Units (each a “Member,” and collectively, the “Members”). This Operating

ODT / Odonate Therapeutics, Inc. ODT-10K-20171231 (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38318 Odonate Therap

ODT / Odonate Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment

odon17in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 676079106 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 676079106 (CUSIP Number) December 31, 2017 (Da

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2018 ODONATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38318 46-2248457 (State or other jurisdiction of incorporation) (Commiss

ODT / Odonate Therapeutics, Inc. / Odonate Holdings, Llc Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Odonate Holdings, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Name, Address and Telephone Number

ODT / Odonate Therapeutics, Inc. / TANG CAPITAL PARTNERS LP Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Odonate Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 676079106 (CUSIP Number) Kevin C. Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Name, Address

ODT / Odonate Therapeutics, Inc. / Boxer Capital, LLC - SC 13D Activist Investment

SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No.

6,250,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-221533 and 333-221931 6,250,000 Shares Common Stock This is an initial public offering of shares of common stock of Odonate Therapeutics, Inc. All of the 6,250,000 shares of common stock are being sold by the company. The initial public offering price of our common stock is $24.00 per share. Prior to this offering, there has

JOINT FILING AGREEMENT

EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.01 par value per share, of Odonate Therapeutics, Inc. and further agree that this Joint Filing Agreemen

- S-1MEF

As filed with the Securities and Exchange Commission on December 6, 2017 Registration No.

Form 8-A

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ODONATE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-2248457 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 4747 Executive Drive, Suite 5

-

VIA EDGAR December 5, 2017 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento, Esq. Erin Jaskot, Esq. Re: Odonate Therapeutics, LLC Registration Statement on Form S-1 (File No. 333-221533) Ladies and Gentlemen: As representatives of the several underwriters of the proposed initial public offering of shares of

-

VIA EDGAR AND EMAIL December 5, 2017 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington D.C. 20549 Attention: Ada D. Sarmento, Esq. Erin Jaskot, Esq. Re: Odonate Therapeutics, LLC Registration Statement on Form S-1 (File No. 333-221533) Dear Mses. Sarmento and Jaskot: Odonate Therapeutics, LLC, a Delaware limited liability company (the ?Company?), r

Form of Indemnification Agreement to be entered into between Odonate Therapeutics, Inc. and each of its directors and executive officers

Exhibit 10.6 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is entered into as of November [ ], 2017 (the ?Effective Date?) by and between Odonate Therapeutics, Inc., a Delaware corporation (the ?Company?), and [ ] (the ?Indemnitee?). RECITALS WHEREAS, the Company has adopted provisions in its Bylaws providing for indemnification and advancement of expenses of its dire

Form of Stock Option Award

Exhibit 10.3 ODONATE THERAPEUTICS, INC. GRANT NOTICE FOR 2017 STOCK OPTION PLAN [INCENTIVE][NONQUALIFIED] STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, Odonate Therapeutics, Inc. (?Odonate? or the ?Company?), hereby grants to Participant named below the [incentive][nonqualified] stock option (the ?Option?) to purchase any part or all of the number of shares of its common stock, par value $0.0

Bylaws of Odonate (incorporated herein by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1 (File No. 333-221533), as filed with the SEC on November 27, 2017)

Exhibit 3.2 BYLAWS OF ODONATE THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Annual Meeting. The annual meeting of stockholders, for the election of directors and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, either within or outside of the State of Delaware, on such date, and at

Certificate of Incorporation of Odonate (incorporated herein by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 (File No. 333-221533), as filed with the SEC on November 27, 2017)

Exhibit 3.1 CERTIFICATE OF INCORPORATION OF ODONATE THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I NAME The name of the corporation is Odonate Therapeutics, Inc. (?Odonate?). ARTICLE II AGENT The address of Odonate?s registered office in the State of Delaware is 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is The Corpora

Form of Underwriting Agreement

Exhibit 1.1 Odonate Therapeutics, Inc. Common Stock, par value $0.01 per share Underwriting Agreement , 2017 Goldman Sachs & Co. LLC, Jefferies LLC As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentle

2017 Stock Option Plan

Exhibit 10.2 ODONATE THERAPEUTICS, INC. 2017 STOCK OPTION PLAN 1. Purpose. The purpose of this Odonate Therapeutics, Inc. 2017 Stock Option Plan (the ?Plan?) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of Odonate Therapeutics, Inc. (?Odonate?) and Odonate?s stockholders by providing stock-based compensation. 2. Definition

2017 Employee Stock Purchase Plan

Exhibit 10.4 ODONATE THERAPEUTICS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the 2017 Employee Stock Purchase Plan, including any sub-plans or appendices hereto (the ?Plan?), is to provide an opportunity for Employees of Odonate Therapeutics, Inc., a Delaware corporation (?Odonate?) and its Participating Subsidiaries to purchase Common Stock of Odonate and thereby to have a

- S-1/A

Table of Contents As filed with the Securities and Exchange Commission on November 27, 2017 Registration No.

Limited Liability Company Operating Agreement of Odonate Holdings, LLC

Exhibit 10.1 LIMITED LIABILITY COMPANY AGREEMENT OF ODONATE HOLDINGS, LLC This Limited Liability Company Agreement (this ?Operating Agreement?) of Odonate Holdings, LLC (?Odonate Holdings?) is made effective as of November 27, 2017 (the ?Effective Date?), with respect to the holders of Units (each a ?Member,? and collectively, the ?Members?). Odonate Holdings and the Members agree as follows: 1. P

License Agreement, dated as of June 3, 2013, with Daiichi Sankyo Company, Limited

Table of Contents Exhibit 10.5 Pursuant to 17 CFR 230.406, confidential information has been omitted in places marked ?* * *? and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission. LICENSE AGREEMENT BETWEEN DAIICHI SANKYO COMPANY, LIMITED AND ODONATE THERAPEUTICS, LLC1 1 As of June 3, 2013, the date of execution o

Power of Attorney

Table of Contents As filed with the Securities and Exchange Commission on November 13, 2017 Registration No.

-

Gibson, Dunn & Crutcher LLP 555 Mission Street San Francisco, CA 94105-0921 Tel 415.

-

Gibson, Dunn & Crutcher LLP 555 Mission Street San Francisco, CA 94105-0921 Tel 415.

-

Gibson, Dunn & Crutcher LLP 555 Mission Street San Francisco, CA 94105-0921 Tel 415.

-

Table of Contents As confidentially submitted to the Securities and Exchange Commission on October 30, 2017 Registration No.

-

Gibson, Dunn & Crutcher, LLP 555 Mission Street San Francisco, CA 94105-0921 Tel 415.

-

Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 29, 2017 Registration No.